Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.
Dr. Massimo Cristofanilli
Advertisement
Dr. Massimo Cristofanilli is the director of Breast Medical Oncology, professor of Medicine, and associate director of Precision Oncology at Weill Cornell Medicine; attending physician at New York-Presbyterian.
Articles by Dr. Massimo Cristofanilli
Advertisement
